142 related articles for article (PubMed ID: 10551714)
21. [A new therapeutic proposal for intermittent claudication. Propionyl-L-carnitine: new indications concerning mechanism of action].
Brevetti G; Martone VD; Corrado S; Silvestro A; Di Donato AM; Di Iorio A
Minerva Cardioangiol; 1998 Sep; 46(9):299-300. PubMed ID: 10021852
[No Abstract] [Full Text] [Related]
22. Levo-propionyl-carnitine improves the effectiveness of supervised physical training on the absolute claudication distance in patients with intermittent claudication.
Andreozzi GM; Leone A; Laudani R; Martin R; Deinit G; Cataldi V
Angiology; 2008; 59(1):84-9. PubMed ID: 18319227
[TBL] [Abstract][Full Text] [Related]
23. Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over study.
Brevetti G; Chiariello M; Ferulano G; Policicchio A; Nevola E; Rossini A; Attisano T; Ambrosio G; Siliprandi N; Angelini C
Circulation; 1988 Apr; 77(4):767-73. PubMed ID: 3280157
[TBL] [Abstract][Full Text] [Related]
24. A systematic review and meta-analysis of propionyl-L-carnitine effects on exercise performance in patients with claudication.
Brass EP; Koster D; Hiatt WR; Amato A
Vasc Med; 2013 Feb; 18(1):3-12. PubMed ID: 23321261
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of the efficacy of propionyl-L-carnitine versus pulsed muscular compressions in diabetic and non-diabetic patients affected by obliterating arteriopathy Leriche stage II.
Riccioni C; Sarcinella R; Palermo G; Izzo A; Liguori M; Koverech A; Messano M; Virmani A
Int Angiol; 2008 Jun; 27(3):253-9. PubMed ID: 18506129
[TBL] [Abstract][Full Text] [Related]
26. Heparan sulfate in the treatment of intermittent claudication: results of a randomized, double-blind, placebo-controlled multicenter trial.
Messa GL; Gelso E
Drugs Exp Clin Res; 2002; 28(1):37-48. PubMed ID: 12073766
[TBL] [Abstract][Full Text] [Related]
27. Effect of cloricromene on intermittent claudication. A randomized, double-blind, placebo-controlled trial in patients treated with aspirin: effect on claudication distance and quality of life. CRAMPS Investigator Group. Cloricromene Randomized Arteriopathy Multicenter Prospective Study.
Gresele P; Migliacci R; Di Sante G; Nenci GG;
Vasc Med; 2000; 5(2):83-9. PubMed ID: 10943584
[TBL] [Abstract][Full Text] [Related]
28. Impact of a 4-week treatment with prostaglandin E1 on health-related quality of life of patients with intermittent claudication.
Mangiafico RA; Messina R; Attinà T; Dell'Arte S; Giuliano L; Malatino LS
Angiology; 2000 Jun; 51(6):441-9. PubMed ID: 10870853
[TBL] [Abstract][Full Text] [Related]
29. A long-term study of policosanol in the treatment of intermittent claudication.
Castaño G; Más Ferreiro R; Fernández L; Gámez R; Illnait J; Fernández C
Angiology; 2001 Feb; 52(2):115-25. PubMed ID: 11228084
[TBL] [Abstract][Full Text] [Related]
30. [Treatment of chronic arterial occlusive disease of the lower limbs with propionyl-1-carnitine in elderly patients].
Terranova R; Luca S
Minerva Med; 2001 Feb; 92(1):61-6. PubMed ID: 11317141
[TBL] [Abstract][Full Text] [Related]
31. Pharmacological treatment of patients with chronic critical limb ischemia: L-propionyl-carnitine enhances the short-term effects of PGE-1.
Milio G; Novo G; Genova C; Luigi Almasio P; Novo S; Pinto A
Cardiovasc Drugs Ther; 2009 Aug; 23(4):301-6. PubMed ID: 19548076
[TBL] [Abstract][Full Text] [Related]
32. [Placebo-controlled double-blind study of the effectiveness of Ginkgo biloba special extract EGb 761 in trained patients with intermittent claudication].
Blume J; Kieser M; Hölscher U
Vasa; 1996; 25(3):265-74. PubMed ID: 8967154
[TBL] [Abstract][Full Text] [Related]
33. Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial. Journal of the American Medical Association 2013; 309: 453-460.
Kurklinsky AK; Levy M
Vasc Med; 2013 Aug; 18(4):234-6. PubMed ID: 23867841
[TBL] [Abstract][Full Text] [Related]
34. Pharmacotherapy of intermittent claudication.
Doggrell SA
Expert Opin Pharmacother; 2001 Nov; 2(11):1725-36. PubMed ID: 11825312
[TBL] [Abstract][Full Text] [Related]
35. A botanical compound, Padma 28, increases walking distance in stable intermittent claudication.
Drabaek H; Mehlsen J; Himmelstrup H; Winther K
Angiology; 1993 Nov; 44(11):863-7. PubMed ID: 8239057
[TBL] [Abstract][Full Text] [Related]
36. Demonstration of the efficacy of ginkgo biloba special extract EGb 761 on intermittent claudication--a placebo-controlled, double-blind multicenter trial.
Peters H; Kieser M; Hölscher U
Vasa; 1998 May; 27(2):106-10. PubMed ID: 9612115
[TBL] [Abstract][Full Text] [Related]
37. Effects of pentoxifylline on severe intermittent claudication.
Reich T; Gillings D
Angiology; 1987 Sep; 38(9):651-6. PubMed ID: 3310744
[TBL] [Abstract][Full Text] [Related]
38. [The clinical and hemodynamic effects of propionyl-L-carnitine in the treatment of congestive heart failure].
Pucciarelli G; Mastursi M; Latte S; Sacra C; Setaro A; Lizzadro A; Nolfe G
Clin Ter; 1992 Nov; 141(11):379-84. PubMed ID: 1493661
[TBL] [Abstract][Full Text] [Related]
39. Reliability of treadmill testing in peripheral arterial disease: a comparison of a constant load with a graded load treadmill protocol.
Labs KH; Nehler MR; Roessner M; Jaeger KA; Hiatt WR
Vasc Med; 1999; 4(4):239-46. PubMed ID: 10613628
[TBL] [Abstract][Full Text] [Related]
40. A comparison of cilostazol and pentoxifylline for treating intermittent claudication.
Dawson DL; Cutler BS; Hiatt WR; Hobson RW; Martin JD; Bortey EB; Forbes WP; Strandness DE
Am J Med; 2000 Nov; 109(7):523-30. PubMed ID: 11063952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
